NASDAQ:EVOK Evoke Pharma (EVOK) Stock Price, News & Analysis → the most reliable asset on earth is making a comeback (From DTI) (Ad) Free EVOK Stock Alerts $0.60 0.00 (0.00%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$0.57▼$0.6450-Day Range$0.59▼$0.7952-Week Range$0.56▼$2.42Volume17,626 shsAverage Volume64,272 shsMarket Capitalization$5.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Evoke Pharma alerts: Email Address Ad Crypto 101 MediaCrypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online Event About Evoke Pharma Stock (NASDAQ:EVOK)Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Read More EVOK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVOK Stock News HeadlinesMarch 25, 2024 | americanbankingnews.comEvoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.comMarch 22, 2024 | finanznachrichten.deEvoke Pharma, Inc.: Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive OfficerMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 21, 2024 | marketwatch.comEvoke Pharma Taps Operating Chief D'Onofrio to Succeed CEO GonyerMarch 21, 2024 | finance.yahoo.comEvoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive OfficerMarch 21, 2024 | globenewswire.comEvoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive OfficerMarch 18, 2024 | msn.comBig change is the only constant in eco: India IncMarch 17, 2024 | seekingalpha.comEvoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 16, 2024 | finance.yahoo.comEvoke Pharma, Inc. (NASDAQ:EVOK): Are Analysts Optimistic?March 15, 2024 | msn.comBrain gain: Hope rises with new dementia treatmentsMarch 15, 2024 | finance.yahoo.comEvoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finanznachrichten.deEvoke Pharma, Inc.: Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 15, 2024 | msn.comEVOK Stock Earnings: Evoke Pharma Misses EPS, Beats Revenue for Q4 2023March 14, 2024 | msn.com‘Would have torn Modi into pieces’: DMK minister TM Anbarasan booked for remarks against PMMarch 14, 2024 | globenewswire.comEvoke Pharma Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 13, 2024 | benzinga.comA Preview Of Evoke Pharma's EarningsMarch 13, 2024 | markets.businessinsider.comEvoke Pharma Inc Registered Shs hosts conference call for investorsMarch 7, 2024 | globenewswire.comEvoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024February 27, 2024 | investing.comEvoke Pharma Inc (EVOK)February 26, 2024 | msn.comConfronting the legacy of the Holocaust in 2024 film ‘Treasure’ - reviewFebruary 26, 2024 | finance.yahoo.comEVOKE PHARMA INC.DL-,0001 (EV00.DU)February 24, 2024 | benzinga.comEvoke Pharma Stock (NASDAQ:EVOK) Dividends: History, Yield and DatesFebruary 22, 2024 | finance.yahoo.comLift Off with Spring Sculpture Exhibitions at Frederik Meijer Gardens & Sculpture ParkFebruary 15, 2024 | money.usnews.comEvoke Pharma IncFebruary 14, 2024 | finance.yahoo.comEvoke Pharma Announces Closing of $7.5 Million Public OfferingFebruary 14, 2024 | globenewswire.comEvoke Pharma Announces Closing of $7.5 Million Public OfferingSee More Headlines Receive EVOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today3/28/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:EVOK CUSIPN/A CIK1403708 Webwww.evokepharma.com Phone(858) 345-1494FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,790,000.00 Net Margins-150.43% Pretax Margin-150.40% Return on Equity-517.99% Return on Assets-91.83% Debt Debt-to-Equity Ratio9.29 Current Ratio2.25 Quick Ratio2.09 Sales & Book Value Annual Sales$5.18 million Price / Sales0.99 Cash FlowN/A Price / Cash FlowN/A Book Value($0.77) per share Price / Book-0.79Miscellaneous Outstanding Shares8,480,000Free Float7,479,000Market Cap$5.13 million OptionableNot Optionable Beta0.21 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. David A. Gonyer R.Ph. (Age 60)Co-Founder, CEO & Director Comp: $666.31kMr. Matthew J. D'Onofrio MBA (Age 54)Co-Founder, President, COO, Secretary & Treasurer Comp: $498.12kDr. Marilyn R. Carlson D.M.D. (Age 76)M.D., RAC., Chief Medical Officer Comp: $444.99kMr. Christopher QuesenberryChief Commercial Officer - Gimoti (TM)Key CompetitorsKazia TherapeuticsNASDAQ:KZIALixte BiotechnologyNASDAQ:LIXTExicureNASDAQ:XCURBright Minds BiosciencesNASDAQ:DRUGKiora PharmaceuticalsNASDAQ:KPRXView All Competitors EVOK Stock Analysis - Frequently Asked Questions How have EVOK shares performed in 2024? Evoke Pharma's stock was trading at $1.0503 at the start of the year. Since then, EVOK stock has decreased by 42.4% and is now trading at $0.6050. View the best growth stocks for 2024 here. Are investors shorting Evoke Pharma? Evoke Pharma saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 72,100 shares, an increase of 21.8% from the February 29th total of 59,200 shares. Based on an average trading volume of 60,100 shares, the short-interest ratio is currently 1.2 days. Approximately 1.1% of the company's stock are sold short. View Evoke Pharma's Short Interest. When is Evoke Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our EVOK earnings forecast. How were Evoke Pharma's earnings last quarter? Evoke Pharma, Inc. (NASDAQ:EVOK) released its quarterly earnings results on Thursday, March, 14th. The specialty pharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter. The specialty pharmaceutical company earned $1.68 million during the quarter. Evoke Pharma had a negative net margin of 150.43% and a negative trailing twelve-month return on equity of 517.99%. When did Evoke Pharma's stock split? Evoke Pharma shares reverse split on the morning of Monday, May 23rd 2022. The 1-12 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What guidance has Evoke Pharma issued on next quarter's earnings? Evoke Pharma issued an update on its FY 2024 earnings guidance on Thursday, March, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $14.0 million-$14.0 million, compared to the consensus revenue estimate of $14.0 million. What other stocks do shareholders of Evoke Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY). Who are Evoke Pharma's major shareholders? Evoke Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Evoke Pharma? Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EVOK) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.